Patient and treatment characteristics of patients who underwent apheresis according to receipt of CAR T-cell therapy
| . | All patients (N = 148) . | Apheresis (N = 148) . | ||
|---|---|---|---|---|
| Characteristic . | CAR T-cell infusion (n = 124) . | No CAR T-cell infusion (n = 24) . | P . | |
| Age, y | .71 | |||
| Median | 60 | 60 | 60 | |
| Range | 18-85 | 18-85 | 31-80 | |
| >60 | 76 (51) | 64 (52) | 12 (50) | .89 |
| Female sex | 42 (28) | 32 (26) | 10 (42) | .14 |
| ECOG PS 2-3 | 30 (20) | 17 (14) | 13 (54) | <.01 |
| Pathology | .39 | |||
| DLBCL | 115 (78) | 95 (77) | 20 (83) | |
| TFL | 24 (16) | 20 (16) | 4 (17) | |
| PMBCL | 9 (6) | 9 (7) | 0 (0) | |
| Cell of origin | .99 | |||
| GCB | 86 (58) | 72 (58) | 14 (58) | |
| Non-GCB | 55 (37) | 46 (37) | 9 (38) | |
| Unknown | 7 (5) | 6 (5) | 1 (4) | |
| Double expresser | .13 | |||
| Yes | 45 (30) | 36 (29) | 9 (38) | |
| No | 76 (51) | 68 (55) | 8 (33) | |
| Unknown | 27 (18) | 20 (16) | 7 (29) | |
| HGBL-DH/TH | .47 | |||
| Yes | 30 (20) | 23 (19) | 7 (29) | |
| No | 107 (72) | 92 (74) | 15 (63) | |
| Unknown | 11 (7) | 9 (7) | 2 (8) | |
| Stage at apheresis | .31 | |||
| I/II | 19 (13) | 18 (15) | 1 (4) | |
| III/IV | 129 (87) | 106 (85) | 23 (96) | |
| IPI ≥3 | 88 (60) | 68 (55) | 20 (83) | .01 |
| Bulky disease (≥10 cm) | 46 (31) | 33 (27) | 13 (54) | .01 |
| Lines of prior therapy, n | .67 | |||
| Median | 3 | 3 | 3 | |
| Range | 2-11 | 2-11 | 2-6 | |
| ≥3 | 110 (74) | 87 (71) | 23 (96) | .01 |
| Serum LDH, IU/L* | ||||
| >ULN | 110 (74) | 87 (71) | 24 (100) | .01 |
| >2× ULN | 45 (32) | 26 (22) | 19 (79) | <.01 |
| BT | .01 | |||
| Any | 81 (55) | 62 (50) | 19 (79) | |
| ST | 61 (41) | 45 (36) | 16 (67) | |
| RT | 11 (7) | 11 (9) | 0 (0) | |
| CMT | 9 (6) | 6 (5) | 3 (13) | |
| PFS, mo | <.01 | |||
| Median | 4.8 | 6.2 | 0.7 | |
| 95% CI | 3.7-6.0 | 4.1-8.3 | 0.5-1.0 | |
| OS, mo | <.01 | |||
| Median | 16.7 | 21.9 | 1.3 | |
| 95% CI | 7.1-26.2 | NE | 0.8-1.8 | |
| . | All patients (N = 148) . | Apheresis (N = 148) . | ||
|---|---|---|---|---|
| Characteristic . | CAR T-cell infusion (n = 124) . | No CAR T-cell infusion (n = 24) . | P . | |
| Age, y | .71 | |||
| Median | 60 | 60 | 60 | |
| Range | 18-85 | 18-85 | 31-80 | |
| >60 | 76 (51) | 64 (52) | 12 (50) | .89 |
| Female sex | 42 (28) | 32 (26) | 10 (42) | .14 |
| ECOG PS 2-3 | 30 (20) | 17 (14) | 13 (54) | <.01 |
| Pathology | .39 | |||
| DLBCL | 115 (78) | 95 (77) | 20 (83) | |
| TFL | 24 (16) | 20 (16) | 4 (17) | |
| PMBCL | 9 (6) | 9 (7) | 0 (0) | |
| Cell of origin | .99 | |||
| GCB | 86 (58) | 72 (58) | 14 (58) | |
| Non-GCB | 55 (37) | 46 (37) | 9 (38) | |
| Unknown | 7 (5) | 6 (5) | 1 (4) | |
| Double expresser | .13 | |||
| Yes | 45 (30) | 36 (29) | 9 (38) | |
| No | 76 (51) | 68 (55) | 8 (33) | |
| Unknown | 27 (18) | 20 (16) | 7 (29) | |
| HGBL-DH/TH | .47 | |||
| Yes | 30 (20) | 23 (19) | 7 (29) | |
| No | 107 (72) | 92 (74) | 15 (63) | |
| Unknown | 11 (7) | 9 (7) | 2 (8) | |
| Stage at apheresis | .31 | |||
| I/II | 19 (13) | 18 (15) | 1 (4) | |
| III/IV | 129 (87) | 106 (85) | 23 (96) | |
| IPI ≥3 | 88 (60) | 68 (55) | 20 (83) | .01 |
| Bulky disease (≥10 cm) | 46 (31) | 33 (27) | 13 (54) | .01 |
| Lines of prior therapy, n | .67 | |||
| Median | 3 | 3 | 3 | |
| Range | 2-11 | 2-11 | 2-6 | |
| ≥3 | 110 (74) | 87 (71) | 23 (96) | .01 |
| Serum LDH, IU/L* | ||||
| >ULN | 110 (74) | 87 (71) | 24 (100) | .01 |
| >2× ULN | 45 (32) | 26 (22) | 19 (79) | <.01 |
| BT | .01 | |||
| Any | 81 (55) | 62 (50) | 19 (79) | |
| ST | 61 (41) | 45 (36) | 16 (67) | |
| RT | 11 (7) | 11 (9) | 0 (0) | |
| CMT | 9 (6) | 6 (5) | 3 (13) | |
| PFS, mo | <.01 | |||
| Median | 4.8 | 6.2 | 0.7 | |
| 95% CI | 3.7-6.0 | 4.1-8.3 | 0.5-1.0 | |
| OS, mo | <.01 | |||
| Median | 16.7 | 21.9 | 1.3 | |
| 95% CI | 7.1-26.2 | NE | 0.8-1.8 | |
Values are n (%) unless otherwise noted. P values in bold indicate statistical significance (≤.05).
NE, not estimable.
LDH data unavailable for 5 patients.